

Using 31-gene expression profile testing to help guide adjuvant therapy and sentinel lymph node biopsy discussions with patients: A case series


Peter Prieto, MD¹

¹University of Rochester Medical Center, Rochester, NY USA



Scan or click here for more info

Workflow incorporating 31-GEP with AJCC staging



Conclusions

- › Immunotherapy has provided significant improvements in advanced-stage melanoma survival, but adverse events can occur in the majority of patients. (Brahmer, et al. J Immun Can 2021)
- › The 31-GEP provides personalized, independent risk stratification to guide shared decision-making discussions with patients about clinical management, imaging surveillance, and adjuvant therapy.
- › The 31-GEP helps identify truly high- or low-risk patients who may benefit from different clinical or treatment decisions, allowing patients and their clinicians to be more confident in their decision-making.

Case 1: 46-year-old female

- › **Clinical:** Bleeding, non-healing, ulcerated lesion on right arm
- › **Tumor:** T3b tumor: 4.0 mm, ulcerated, >2 mitoses/mm²
- › SLNB Positive
- › Stage IIIC
- › Staging imaging found solitary lung lesion
- › **31-GEP: Class 2B**
- › **i31-SLNB: 31.8%**
- › **Could this patient have avoided an SLNB and simply proceeded to staging imaging and systemic immunotherapy?**

Case 2: 80-year-old male

- › **Clinical:** Ulcerated lesion of the posterior neck
- › **Tumor:** T2a tumor: 1.6 mm, no ulceration, >1 mitoses/mm², no regression
- › SLNB Positive
- › Stage IIIA
- › **31-GEP: Class 1A**
- › **31-GEP result helped guide adjuvant therapy discussions with patient**
- › Patient declined adjuvant immunotherapy after discussion with medical and surgical oncologists.

Case 3: 58-year-old male

- › **Clinical:** Bleeding, evolving nevus of the right leg
- › **Tumor:** T2a tumor: 1.35 mm, no ulceration, 1 mitoses/mm², no regression
- › SLNB Positive
- › Stage IIIA
- › **31-GEP: Class 2B**
- › **i31-SLNB: 18.4%**
- › **31-GEP result guided patient and clinician personalized treatment planning**
- › Patient received adjuvant immunotherapy (nivolumab) and had no evidence of disease 11 months later